Sanxin Medical released its 2026 half-year report. Operating revenue was 837 million yuan, up 10.0% year on year. Net profit attributable to the parent was 132 million yuan, up 14.8% year on year. Net profit attributable to the parent after deducting non-recurring items was 122 million yuan, up 17.8% year on year. Net operating cash flow was 155 million yuan, down 17.8% year on year. In the second quarter, operating revenue was 428 million yuan, up 6.9% year on year, and net profit attributable to the parent was 63.76 million yuan, up 3.9% year on year. The company's main business is in the medical device industry, especially in blood purification, drug delivery devices, and cardiothoracic surgery. During the reporting period, revenue from blood purification products increased compared with the same period last year, becoming the core engine of the company's high-quality development.
Jiangxi Sanxin Medtec Co LtdFirst-half net profit up 14.8% and revenue up 10% year on year.
